Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Iovance Biotherapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was €-273.5 Mil. Iovance Biotherapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was €554.6 Mil. Therefore, Iovance Biotherapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -49.31%.
The historical rank and industry rank for Iovance Biotherapeutics's Return-on-Tangible-Asset or its related term are showing as below:
HAM:2LB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -73.09 Med: -51.4 Max: -38.12
Current: -55.24
During the past 13 years, Iovance Biotherapeutics's highest Return-on-Tangible-Asset was -38.12%. The lowest was -73.09%. And the median was -51.40%.
HAM:2LB's Return-on-Tangible-Asset is ranked worse than 62.75% of 1412
companies
in the Biotechnology industry
Industry Median: -35.66
vs HAM:2LB: -55.24
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Iovance Biotherapeutics Return-on-Tangible-Asset Related Terms
Iovance Biotherapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Iovance Biotherapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:2LB vs SNDX, GLUE, TYRA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Iovance Biotherapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -49.31% mean?
Iovance Biotherapeutics (HAM:2LB) has a Return-on-Tangible-Asset of -49.31% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Iovance Biotherapeutics and its competitors. According to the industry distribution chart, Iovance Biotherapeutics ranks #886 out of 1412 companies in the Biotechnology industry, placing it in the top 62.7%.
Is Iovance Biotherapeutics' Return-on-Tangible-Asset too high?
Iovance Biotherapeutics' current Return-on-Tangible-Asset is -49.31%. Based on the distribution chart, Iovance Biotherapeutics ranks #886 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Return-on-Tangible-Asset compare to SNDX and GLUE?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #886 out of 1412 companies for Return-on-Tangible-Asset. This places Iovance Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Return-on-Tangible-Asset is -49.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (HAM:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €17.09, compared to a current price of €3.78 — trading 77.9% below its estimated fair value. The current Return-on-Tangible-Asset is -49.31%. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Iovance Biotherapeutics (HAM:2LB), the current Return-on-Tangible-Asset is -49.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (HAM:2LB) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of €3.78 is trading 77.9% below its estimated GF Value™ of €17.09.
GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.
Key valuation signals for HAM:2LB:
Return-on-Tangible-Asset: -49.31%
GF Value™: €17.09 vs. price of €3.78 (77.9% below fair value)
No single metric tells the full story. See the HAM:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score
Get the complete analysis for HAM:2LB
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:2LB has been successfully added to your 
